Vertex Extends FDA Approval of CASGEVY to Children Aged 2 and Older for Sickle Cell Disease and Beta Thalassemia

Vertex Pharmaceuticals Inc. (VRTX) announced that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY, a gene-edited therapy, for pediatric patients aged 2 years and older with sickle cell disease (SCD) experiencing vaso-occlusive crises or transfusion-dependent beta thalassemia.

This approval marks CASGEVY as the first genetic therapy authorized for children as young as 2 for both conditions, extending its availability beyond the previous indication for patients 12 years and older. The update is expected to provide treatment access to approximately 5,500 additional children in the U.S.

CASGEVY functions by modifying a patient’s own hematopoietic stem cells to enhance fetal hemoglobin (HbF) production, thereby reducing red blood cell sickling in SCD and decreasing reliance on blood transfusions in beta thalassemia. Developed through Vertex’s gene-editing platform, the therapy has demonstrated consistent efficacy across age groups, offering a potential long-term solution for patients with historically limited therapeutic options.

“This advancement underscores our commitment to redefining treatment possibilities, much like we did with cystic fibrosis, and to transforming outcomes for individuals affected by sickle cell disease and transfusion-dependent beta thalassemia,” said Reshma Kewalramani, M.D., CEO and President of Vertex.

Clinicians highlighted the significance of early intervention. “This approval brings renewed hope for young patients and their families, as addressing these conditions earlier may mitigate long-term complications associated with these life-shortening disorders,” remarked Haydar Frangoul, M.D., M.S., Medical Director of HCA Healthcare’s Sarah Cannon Transplant and Cellular Therapy Program.

Vertex has established a network of over 75 authorized treatment centers nationwide to facilitate CASGEVY administration, ensuring accessibility through established care and reimbursement frameworks. The company reported that CASGEVY generated $43 million in revenue during the first quarter of 2026.

This regulatory milestone reinforces Vertex’s efforts to expand transformative therapies for severe blood disorders, particularly benefiting pediatric populations with unmet medical needs.

Source link